The SURMOUNT-1 trial published in NEJM demonstrated 20.9% mean body weight reduction at 72 weeks on 15mg weekly tirzepatide
Alarm symptoms that warrant urgent medical attention include: Difficulty swallowing (dysphagia) or painful swallowing (odynophagia) Unexplained weight loss not attributable to the expected therapeutic effect of Zepbound Persistent vomiting, especially if containing blood or coffee-ground material Black, tarry stools or visible blood in stool (suggesting gastrointestinal bleeding) Severe chest pain that could indicate cardiac issues rather than reflux New or worsening symptoms of anemia (fatigue, pallor, shortness of breath) Severe, persistent abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper quadrant pain, fever, or jaundice (possible gallbladder disease) These symptoms may indicate complications such as esophagitis, esophageal stricture, Barrett's esophagus, or other serious conditions requiring diagnostic evaluation
GLP-1 drugs have dominated headlines in recent yearsbut what exactly are they
The absolute number depends on three factors: starting body composition, dose escalation speed, and the size of the calorie deficit the drug creates
